Please check your internet connection and try again.
# Aztreonam-Avibactam
## Overview
Aztreonam-avibactam is a fixed-dose combination of a monobactam antibiotic and a non-beta-lactam beta-lactamase inhibitor. It is specifically designed to combat metallo-beta-lactamase (MBL)-producing Gram-negative organisms, which are often resistant to standard beta-lactamase inhibitor combinations.
## Primary Indications
Treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative organisms, including those producing MBLs (e.g., NDM, VIM, IMP).
## Adult Dosing
* **Standard Dose:** 500 mg aztreonam / 137.5 mg avibactam (or equivalent formulation per local product labeling, e.g., 2g/500mg) administered IV every 8 hours.
* **Infusion Time:** Administer as an intravenous infusion over 2 hours.
* *Note: Dosing can vary by regional regulatory approval (e.g., FDA vs. EMA); always verify total daily dose against specific local institutional protocols.*
## Pediatric Dosing
Safety and efficacy in pediatric patients (younger than 18 years) have not been established. Use in this population is generally considered off-label and requires consultation with a pediatric infectious disease specialist.
## Dose Adjustments
* **Renal Impairment:** Dosage must be adjusted based on creatinine clearance (CrCl). If CrCl < 50 mL/min, the dosing interval should be extended or the dose reduced as specified by local product labeling.
* **Hepatic Impairment:** No standard dosage adjustment required.
## Contraindications
* Known hypersensitivity to any component of the formulation.
* History of severe hypersensitivity reactions (e.g., anaphylaxis) to any other beta-lactam antibiotic.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, infusion site reactions, and increased hepatic transaminases.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypersensitivity reactions, rash, and neutropenia.
## Key Drug Interactions
* **Probenecid:** May increase serum concentrations of aztreonam.
* **Synergy:** Often combined with other agents (e.g., colistin or tigecycline) in clinical practice for multidrug-resistant organisms; review for synergistic toxicity.
## Monitoring
* **Renal Function:** Monitor baseline and periodic CrCl to inform dose adjustments.
* **Infection Response:** Monitor clinical signs and symptoms, culture results, and inflammatory markers (e.g., CRP, procalcitonin).
* **Safety:** Monitor for symptoms of *C. difficile* (severe diarrhea) and evidence of hypersensitivity reactions.
## Clinical Pearls
* **MBL Activity:** This is one of the few agents active against MBL-producing *Enterobacterales* and *Pseudomonas aeruginosa*.
* **Coverage:** It does *not* cover Gram-positive organisms (e.g., Staphylococci, Enterococci) or anaerobic bacteria. Additional coverage is required if these are suspected.
* **Stability:** Ensure correct dilution and infusion rate; stability varies significantly after reconstitution.
* **Stewardship:** Reserve for documented or highly suspected MBL-producing infections to prevent the development of resistance.
***
*Disclaimer: This information is for educational purposes only and does not constitute medical advice. Dosing and clinical practices vary by region and institution. Always verify current prescribing information, institutional guidelines, and regional regulatory approvals before administering medication.*
